Teva Pharmaceutical Industries Limited (TEVA)
| Previous Close | 13.95 |
| Open | 14.57 |
| Bid | 15.59 x 1400 |
| Ask | 15.57 x 1800 |
| Day's Range | 14.54 - 15.73 |
| 52 Week Range | 7.09 - 15.73 |
| Volume | |
| Avg. Volume | 9,288,291 |
| Market Cap | 17.799B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | N/A |
- Investor's Business Daily
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
- Reuters
REFILE-UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue rises
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose. The world's largest generic drugmaker said on Wednesday it earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Teva said its bottom line was hurt mainly by higher impairments of tangible assets largely related to the classification of a business in its international markets segment as held for sale, as well as restructuring costs.
- Reuters
Teva Pharm Q1 profit misses estimates, revenue rises
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose. The world's largest generic drugmaker said on Wednesday it earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Teva said its bottom line was hurt mainly by higher impairments of tangible assets largely related to the classification of a business in its international markets segment as held for sale, as well as restructuring costs.
